Veracyte, Inc. (VCYT) stock
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)
Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –
Veracyte total assets
Total assets on the balance sheet at the end of each period.
Veracyte's total assets was $1.49B at Jun 30, 2026. For fiscal 2025 it was $1.41B, up 8.2% from the year before. Over ten years it grew 34.0% a year on average. The highest annual figure on record is $1.41B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.41B | +8.2% |
| FY2024 | Dec 31, 2024 | $1.30B | +16.6% |
| FY2023 | Dec 31, 2023 | $1.11B | -3.6% |
| FY2022 | Dec 31, 2022 | $1.16B | -2.6% |
| FY2021 | Dec 31, 2021 | $1.19B | +159.8% |
| FY2020 | Dec 31, 2020 | $457.16M | +66.1% |
| FY2019 | Dec 31, 2019 | $275.21M | +128.1% |
| FY2018 | Dec 31, 2018 | $120.64M | +53.3% |
| FY2017 | Dec 31, 2017 | $78.67M | -22.1% |
| FY2016 | Dec 31, 2016 | $101.03M | +34.3% |
| FY2015 | Dec 31, 2015 | $75.25M | +16.1% |
| FY2014 | Dec 31, 2014 | $64.84M | -18.6% |
| FY2013 | Dec 31, 2013 | $79.63M | +317.6% |
| FY2012 | Dec 31, 2012 | $19.07M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.49B | +10.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.44B | +9.2% |
| Q4 FY2025 | Dec 31, 2025 | $1.41B | +8.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.37B | +7.3% |
| Q2 FY2025 | Jun 30, 2025 | $1.34B | +8.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.32B | +9.6% |
| Q4 FY2024 | Dec 31, 2024 | $1.30B | +16.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.28B | +13.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.23B | +6.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.20B | +3.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.11B | -3.6% |
| Q3 FY2023 | Sep 30, 2023 | $1.12B | -0.1% |
| Q2 FY2023 | Jun 30, 2023 | $1.16B | +1.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.16B | -1.4% |
| Q4 FY2022 | Dec 31, 2022 | $1.16B | -2.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.13B | -5.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.14B | +11.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.17B | +14.5% |
| Q4 FY2021 | Dec 31, 2021 | $1.19B | +159.8% |
| Q3 FY2021 | Sep 30, 2021 | $1.19B | +161.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.03B | +300.2% |
| Q1 FY2021 | Mar 31, 2021 | $1.03B | +283.8% |
| Q4 FY2020 | Dec 31, 2020 | $457.16M | +66.1% |
| Q3 FY2020 | Sep 30, 2020 | $454.15M | +74.5% |
| Q2 FY2020 | Jun 30, 2020 | $256.74M | +1.7% |
| Q1 FY2020 | Mar 31, 2020 | $267.10M | +116.2% |
| Q4 FY2019 | Dec 31, 2019 | $275.21M | +128.1% |
| Q3 FY2019 | Sep 30, 2019 | $260.31M | +118.6% |
| Q2 FY2019 | Jun 30, 2019 | $252.38M | +285.5% |
| Q1 FY2019 | Mar 31, 2019 | $123.54M | +73.5% |
| Q4 FY2018 | Dec 31, 2018 | $120.64M | +53.3% |
| Q3 FY2018 | Sep 30, 2018 | $119.08M | +42.3% |
| Q2 FY2018 | Jun 30, 2018 | $65.46M | -25.9% |
| Q1 FY2018 | Mar 31, 2018 | $71.19M | -23.1% |
| Q4 FY2017 | Dec 31, 2017 | $78.67M | -22.1% |
| Q3 FY2017 | Sep 30, 2017 | $83.66M | +20.1% |
| Q2 FY2017 | Jun 30, 2017 | $88.35M | – |
| Q1 FY2017 | Mar 31, 2017 | $92.61M | – |
| Q4 FY2016 | Dec 31, 2016 | $101.03M | – |
| Q3 FY2016 | Sep 30, 2016 | $69.65M | – |
See a number that looks wrong?